|
|
|
European Pharmaceutical Contractor
|
Pharmaceutical companies in Europe and North America are feeling pressure from all sides. Government agencies, constrained by ever-tightening budgets, are limiting reimbursement levels. Fewer high-revenue 'blockbuster' drugs are in the pipeline - and many of the blockbusters already in the market are going off patent, opening the door to the competitive onslaught of the generics. Meanwhile, regulators keep setting the bar higher for new drugs, while making it tougher to keep some existing drugs on the market.
The challenge for pharmaceutical companies is a formidable one: how to cope with these pressures while at the same time increasing revenues and protecting profit margins. Increasingly, these companies are looking to enhanced supply chain efficiency as a way of responding to the challenge. One of the most promising opportunities for enhanced efficiency lies in contract manufacturing, or outsourcing.
By streamlining the supply chain through successful contract management, companies can reduce time to market through faster product launches and lower operating costs - two advantages that translate directly to the bottom line. They can also act with greater flexibility and responsiveness while reducing the capital investment requirements of the product. But it's not enough to simply farm out a manufacturing job to a vendor and then walk away. To succeed at outsourcing, pharmaceutical companies must comprehensively manage the contract manufacturing relationship. This is a continuing requirement that incorporates four interconnected key dimensions:
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Geoff Tomlinson, Principal and Harald Geimer, Director of PRTM
Geoff Tomlinson is a Principal of management consultants PRTM. His consulting experience includes work with companies across Europe and the United States on supply chain management, marketing and sales initiatives. These engagements have covered a range of industries including pharmaceutical, medical devices and diagnostics, automotive, aerospace, transportation and consumer goods.
Prior to consulting, Geoff held management positions with Rank Hovis McDougall in sales, production and quality. He holds a degree in Biological Sciences from Exeter University, and a combined MBA from Manchester Business School and Rotterdam School of Management.
Harald Geimer is a Director in the Worldwide Life Sciences Practice of PRTM. His 14 years of consulting experience includes helping companies in the pharmaceutical, biotech, chemicals, and medical devices industries improve their performance in supply chain management and product development.
His expertise also includes business process re-engineering in logistics, and marketing and service development in the areas of purchasing and supply management. Harald holds a Master's degree in Business Studies and Engineering from the Technical University in Darmstadt, Germany.
|
|
|
|
|
|
 |
Industry Events |
 |
6th European Forum for Qualified Person for Pharmacovigilance (QPPV)
24-26 April 2012, London, UK
This event is for European qualified persons for pharmacovigilance; deputy qualified persons; senior pharmacovigilance regulators and inspectors; CROs and consultants providing QPPV services; and national responsible persons for pharmacovigilance.
More info >> |
|
 |
News and Press Releases |
 |
Greenphire and Merge Healthcare Form Exclusive Partnership to Integrate Clinical Payment and EDC Platforms
Greenphire announced today that it has
formed an exclusive strategic partnership with the clinical trials division of
Merge Healthcare (NASDAQ: MRGE), a leading provider of clinical
trial solutions, to offer integrated functionality between Merge’s EDC
technology and Greenphire’s eClinicalGPS site and vendor payment management
technology.
More info >> |
|
|
